Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC-guided Neoadjuvant Therapy for HER2+ Breast Cancer
NCT04750122Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, carboplatin in HER2-positive breast cancer, sponsored by Peking University People's Hospital. Started Mar 2021; status: recruiting.
02
Drugs
docetaxelcarboplatin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04750122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750122.